![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, December 09, 2023 11:09:27 PM
Re: None
Saturday, November 18, 2023 2:46:09 PM
Post#
648653
of 654707
SNO 2023 DCVax-L discussion transcript from PeerView X account, courtesy ATLinsider.
Note - I did the best I could with Dr. Ashkan's accent.
1:03:48: Manmout Ahluwalia: …there is also work with DCVax which Dr. Brem was involved with that study. Dr. Brem, do you want to highlight the data from that…
Dr. Stephen Brem: We have an expert, Dr. Keyoumars Ashkan from London who is the second author to Linda Liau on our paper in JAMA Oncology this year and I was talking with him before the meeting and things are moving forward, and…do you want to comment?
Dr. Ashkan: Thank you very much Steve. Yes, most of you may have heard about DCVax which is a personalized form of treatment. What was very specific in Dr. King’s presentation was that the many difficulties of glioblastomas is that they are very heterogeneous – no two tumors are the same. So what does that mean? So surgical therapies – and I’m a surgeon – can never be the answer because we cannot resect every single cell. You’ll remember that there were cases of spinal cord GBM, and people transacted about the core, and guess what? There is still GBM many many years later. And secondly because they are so heterogeneous the blanket of treatment, radiotherapy, chemotherapy cannot work because you are dealing with an extremely difficult tumor. The way to address that would be to make the treatment totally personalized to that patient. And in my mind there’s nothing stronger than using the patient's own tumor to produce the treatment, and there’s nothing stronger in my mind than immunotherapy, just like we managed to achieve with COVID. So in view of that you may have seen the results which were published last year in JAMA Oncology which showed that in newly diagnosed GBMs there was an average of a 3 month overall survival benefit compared to external controls, and in the methylated cohort that was 9 months. There was also in recurring GBMs, there was evidence of survival benefit over 6 months and was the first study in 28 years to show an actual benefit in recurring GBM that we haven’t seen elsewhere.
So obviously the next step is to get this drug approved in the UK, where it seems a bit simpler, more efficient pathway to approval which is good news, and we are trying to get the drug approved first in the UK and then beyond that we can move on to the US’s FDA, ect., and so as we speak we are preparing submissions to the MHRA, which is the UK version of the FDA, for regulatory approval and hopefully in the next few months we will hear back. So that was a very quick statement, thank you very much.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM